In this paper we report a review of the results obtained in the last few years by our
group in the development of ruthenium(III) complexes characterized by the presence of
sulfoxide ligands and endowed with antitumor properties. In particular, we will focus on
ruthenates of general formula Na[trans-RuCl4(R1R2SO)(L)], where R1R2SO =
dimethylsulfoxide (DMSO) or tetramethylenesulfoxide (TMSO) and L = nitrogen donor
ligand. The chemical behavior of these complexes has been studied by means of
spectroscopic techniques both in slightly acidic distilled water and in phosphate buffered
solution at physiological pH. The influence of biological reductants on the chemical
behavior is also described. The antitumor properties have been investigated on a number
of experimental tumors. Out of the effects observed, notheworthy appears the capability
of the tested ruthenates to control the metastatic dissemination of solid metastasizing
tumors. The analysis of the antimetastatic action, made in particular on the MCa
mammary carcinoma of CBA mouse, has demonstrated a therapeutic value for these
complexes which are able to significantly prolong the survival time of the treated
animals. The antimetastatic effect is not attributable to a specific cytotoxicity for
metastatic tumor cells although in vitro experiments on pBR322 double stranded DNA
has shown that the test ruthenates bind to the macromolecule, causing breaks
corresponding to almost all bases, except than thymine, and are able to cause interstrand
bonds, depending on the nature of the complex being tested, some of which results active
as cisplatin itself.
Molecular self-assembly is a topic attracting intense scientific interest. Various strategies have been developed for construction of molecular aggregates with rationally designed properties, geometries, and dimensions that promise to provide solutions to both theoretical and practical problems in areas such as drug delivery, medical diagnostics, and biosensors, to name but a few. In this respect, gold nanoparticles covered with self-assembled monolayers presenting nanoscale surface patterns—typically patched, striped or Janus-like domains—represent an emerging field. These systems are particularly intriguing for use in bio-nanotechnology applications, as presence of such monolayers with three-dimensional (3D) morphology provides nanoparticles with surface-dependent properties that, in turn, affect their biological behavior. Comprehensive understanding of the physicochemical interactions occurring at the interface between these versatile nanomaterials and biological systems is therefore crucial to fully exploit their potential. This review aims to explore the current state of development of such patterned, self-assembled monolayer-protected gold nanoparticles, through step-by-step analysis of their conceptual design, synthetic procedures, predicted and determined surface characteristics, interactions with and performance in biological environments, and experimental and computational methods currently employed for their investigation.
The increasing emergence of multidrug-resistant microorganisms represents one of the greatest challenges in the clinical management of infectious diseases, and requires the development of novel antimicrobial agents. To this aim, we
de novo
designed a library of Arg-rich ultra-short cationic antimicrobial lipopeptides (USCLs), based on the Arg-X-Trp-Arg-NH
2
peptide moiety conjugated with a fatty acid, and investigated their antibacterial potential. USCLs exhibited an excellent antimicrobial activity against clinically pathogenic microorganisms, in particular Gram-positive bacteria, including multidrug resistant strains, with MIC values ranging between 1.56 and 6.25 μg/mL. The capability of the two most active molecules, Lau-RIWR-NH
2
and Lau-RRIWRR-NH
2,
to interact with the bacterial membranes has been predicted by molecular dynamics and verified on liposomes by surface plasmon resonance. Both compounds inhibited the growth of
S
.
aureus
even at sub MIC concentrations and induced cell membranes permeabilization by producing visible cell surface alterations leading to a significant decrease in bacterial viability. Interestingly, no cytotoxic effects were evidenced for these lipopeptides up to 50–100 μg/mL in hemolysis assay, in human epidermal model and HaCaT cells, thus highlighting a good cell selectivity. These results, together with the simple composition of USCLs, make them promising lead compounds as new antimicrobials.
The combinational treatment between the selective antimetastatic agent, sodium-transrutheniumtetrachloridedimethylsulfoxideimidazole, Na[trans-RuCI4(DMSO)lm], and the cytotoxic drug 5-fluorouracil (5-FU) on primary tumor growth and on the survival time of experimental tumors results in an effect significantly greater than that of each single agent used alone either with the solid metastasizing MCa mammary carcinoma of the CBA mouse or with the lymphocytic leukemia P388 and its platinum resistant P388/DDP subline. Thus the inorganic compound Na[transRuCI4(DMSO)Im], known for its potent and selective antimetastatic effects, positively interacts with the antitumor action of an organic anticancer agent such as 5-FU on both a solid metastasizing tumor and a tumor of lymphoproliferative type. In particular, the effects of the combinational treatment on the survival time of tumor bearing mice seem to be related to the selective antimetastatic activity of the ruthenium complex that joins the potent cytotoxicity of 5-FU for the tumor. Moreover, these data show that Na[trans-RuCI4(DMSO)lm] is almost as effective on the subline of P388 made resistant to cisplatin as it was on the parental line.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.